GlassScriptPhysician profile
Beth Therese Moreno
NPI 1992283493
$2,533.45
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $730 · 2023: $1,327 · 2024: $54.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $717.77 | 2021-2023 | |
| Novo Nordisk INC | $289.49 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $240.60 | 2021-2023 | Breztri, Farxiga |
| Astellas Pharma US INC | $182.97 | 2023 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $95.73 | 2022-2023 | Quviviq |
| Pfizer INC. | $92.91 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.16 | 2021-2023 | Trulance, Xifaxan |
| Hologic Sales and Service, LLC | $82.39 | 2022-2023 | Aptima |
| Glaxosmithkline, LLC. | $76.81 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.46 | 2022-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $65.45 | 2022 | |
| Amgen INC. | $57.69 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $55.66 | 2023 | Janumet, Belsomra, Januvia |
| Lilly USA, LLC | $51.69 | 2021-2023 | Mounjaro |
| Allergan, INC. | $44.47 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $42.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.32 | 2024 | |
| Eisai INC. | $34.10 | 2021 | |
| Biogen, INC. | $31.85 | 2021 | |
| Dexcom, INC. | $22.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.33 | 2022 | |
| Genentech USA, INC. | $18.28 | 2021 | |
| Amarin Pharma, INC. | $18.03 | 2021 | |
| Baxter Healthcare | $17.52 | 2023 | Hillrom - Retinavue 700 Imager |
| Almatica Pharma LLC | $15.76 | 2021 | |
| Phadia US INC. | $14.90 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.61 | 2024 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $14.27 | 2023 | |
| Optinose US, INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.